SNY - IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

2024-02-12 15:09:25 ET

Summary

• IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 2024.
• The global lupus market is projected to grow to $6.78 billion by 2032 and the global Rheumatoid Arthritis drugs market size is projected to reach $38.61 billion by 2032.
• Two ongoing studies, one single-arm and one randomized, using Aplitabart for the treatment of patients with 2nd-line metastatic colorectal cancer, expected in the 2nd half of 2024.
• The global colorectal cancer market is expected to reach $24.08 billion by 2028.

IGM Biosciences, Inc. ( IGMS ) has built a substantial pipeline full of a few clinical candidates that have been progressing in the clinic. One such drug would be imvotamab, which is a CD20 X CD3 bispecific T cell engaging antibody being developed for the treatment of patients with autoimmune disorders. It is already advancing two phase 1b studies using this drug to treat patients with severe systemic lupus erythematosus ((SLE)) and rheumatoid arthritis ((RA)) respectively. Why I believe that investors should keep an eye on this company is because it is expected that initial results from both of these phase 1b studies are going to be released in the 2nd half of 2024....

For further details see: